HIV pharmacology/med chem Flashcards

(38 cards)

1
Q

HIV has what kind of nucleic acid structure

A

ssRNS with reverse transcriptase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CD4 role in HIV life cycle

A

CD4 is on surface of T cells/macrophage and the HIV virion attaches to CD4, allowing entrance into the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

sequence of events in HIV life cycle

A
  1. fusion of HIV to host cell
  2. RNA, RT, integrase, and proteins enter
  3. viral DNA is formed by RT
  4. DNA is integrated with host DNA
  5. new viral RNA is made, and viral proteins come as result
  6. viral RNA and proteins moves to surface
  7. virus is released and protease makes mature proteins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

classes of HIV drugs

A
  • NRTIs
  • NNRTIs
  • protease inhibitors
  • integrase inhibitors
  • entry inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

NRTIs MoA

A

replace DNA/RNa components, but lack 3’ OH so they terminate the elongation chain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NRTI resistance

A

associated with mutations in pol gene that encodes for RT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NRTI adverse effects

A

mitochondrial toxicity leading to:

  • neuropathy
  • myopathy
  • hepatic steatosis with lactic acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NRTI drugs

A
zidovudine*not as important*
lamivudine
abacavir
tenofovir
emtricitabine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

zidovudine features

A

very short half life so dosing is 2-6 times per day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

lamivudine features

A
  • once daily dosing
  • can reverse zidovudine resistance
  • renal dosing is very important
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

emtricitabine features

A

more potent than lamivudine with less severe side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tenofovir features

A
  • nucleoTIDE analog, not nucleoside
  • prodrug
  • poor outcomes when combined with other drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NNRTI MoA

A

inhibit RT allosterically by binding noncompetitively at a distinct site from NRTIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

notable ADME for NNRTI

A

all are metabolized by p450s so they are prone to drug interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

NNRTI resistance

A

RT mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

NNRTI side effects

A

severe rash

CNS symptoms

17
Q

NNRTI drugs

A

efavirenz
etravirine
rilpivirine

18
Q

efavirenz features

A

don’t use with GERD drugs

19
Q

etravirine features

A
  • no cross resistance with other NNRTIs

- pregnancy class B

20
Q

rilpivirine features

A

-pregnancy class B

21
Q

protease inhibitors MoA

A

inhibit the protease that matures viral proteins at the end of the life cycle

22
Q

protease inhibitors ADME

A

metabolized by 3A4

23
Q

protease inhibitors adverse effects

A
  • GI intolerance

- lipodystrophy

24
Q

protease inhibitor drugs

A

ritonavir
atazanavir
darunavir

25
ritonavir use
because it is the most potent 3A4 inhibitor it is used to keep other drugs going longer, and not so much for its antiviral activity
26
drugs used as 3A4 inhibitors to increase half life of other drugs
ritonavir | cobicistat
27
atazanavir features
good tolerability with once daily dosing
28
darunavir features
1st line option due to its high antiviral activity
29
integrase inhibitors MoA
prevents transfer of viral DNA into host DNA (specifically inhibits strand transfer)
30
integrase inhibitor ADME
not 3A4 inhibitors
31
integrase inhibitor adverse effects
``` insomnia fatigue headache altered cholesterol hypersensitivity reactions ```
32
integrase inhibitor drugs
raltegravir | dolutegravir
33
drug that can cause stevens johnsons
raltegravir
34
entry inhibitor MoA
prevents viral entry by blocking gp120 attachment to CCR5
35
entry inhibitor drug
maraviroc
36
why is combo therapy most effective in HIV
HIV has a very high mutation rate
37
what modification is needed to make NRTIs active
phosphorylation (3 phosphates needed)
38
when using multiple NRTIs what consideration must be made when choosing
the bases they mimic, double dipping doesn't add any benefit